PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies.

Lee, Elizabeth K; Matulonis, Ursula A

Lee, Elizabeth K; Matulonis, Ursula A.

Affiliation

Lee EK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215-5450, USA.
Matulonis UA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215-5450, USA.

Cancers (Basel) ; 12(8)2020 Jul 25.

Article in En | MEDLINE | ID: mdl-32722408

Key words

BRCA; DNA damage repair; PARP inhibitor; PARP inhibitor resistance; homologous recombination; ovarian cancer; replication fork

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Cancers (Basel) Year: 2020 Document type: Article Affiliation country:

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Cancers (Basel) Year: 2020 Document type: Article Affiliation country: